Does the DPP4 Inhibitor (Sitagliptin) Increase Endometrial Mesenchymal Stem Cells in Women with Recurrent Miscarriage?

Trial Profile

Does the DPP4 Inhibitor (Sitagliptin) Increase Endometrial Mesenchymal Stem Cells in Women with Recurrent Miscarriage?

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Sitagliptin (Primary)
  • Indications Spontaneous abortion
  • Focus Therapeutic Use
  • Acronyms SIMPLANT
  • Most Recent Events

    • 05 Sep 2017 Last checked against ISRCTN: Current Controlled Trials.
    • 02 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top